-- Tasisulam (ASAP) - Currently in Phase II, tasisulam has exhibited properties resembling a targeted agent as well as a cytotoxic. The company is testing the anti-tumor activity of tasisulam in several ongoing Phase II studies. Potential registration studies could begin in 2009.
-- GLP-Fc - A Phase II/III adaptive, seamless trial was initiated in early 2008 for the company's leading proprietary GLP-1 asset, a novel Fc-fusion protein GLP-1 analog, or GLP-Fc. Two other Phase II studies of GLP-Fc are also underway in over 400 patients. The company expects safety and efficacy data from the first of these two studies to become available in 2009.
-- Inflammation - The company has made a strong commitment to research in inflammation, as evidenced by four leading internal antibody candidates. IL-17 is progressing into larger Phase II clinical trials in the near future, while IL-23 entered Phase I in 2008. The company also anticipates initiating larger Phase II clinical trials for its BAFF antagonist antibody and IL-1beta in the near future.
Dr. Eric Rowinsky, M.D., executive vice president and chief medical officer of Lilly's wholly-owned subsidiary ImClone Systems, reviewed the numerous additional indications being pursued for Erbitux, as well as the later-stage oncology compounds currently in development.
-- ERBITUX(R) - In addition to its approved indications, Erbitux is also being studied in numerous cancer types, including colorectal, head and neck, non-small cell lung, gastric and esophageal.
-- IMC-1121B is a fully-human monoclonal antibody that targets the
vascular endothelial growth factor (VEGF) receptor. Phase II studies are
underway for metastatic melanoma, renal, liver, ovarian, prostate and
non-small cell lung cancers. Metastatic breast cancer is in Phase III testing,
while Phase III testing in gastric cancer is expected to begin in 20
|SOURCE Eli Lilly and Company|
Copyright©2008 PR Newswire.
All rights reserved